Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 375

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes

Asch, David A., Hershey, John C., Dekay, Michael L., Pauly, Mark V., Patton, James P., Jedrziewski, M. Kathryn, Frei, Frances, Giardine, Rose, Kant, Jeffrey A., Mennuti, Michael T.·1998·Medical Decision Making

Abstract

Objectives. To evaluate the costs and clinical effects of 16 alternative strategies for cystic fibrosis (CF) carrier screening in the reproductive setting; and to test the sensitivity of the results to assumptions about cost and detection rate, stakeholder perspective, DNA test specificity, chance of nonpaternity, and couples' reproductive plans. Method. Cost-effectiveness analysis. Results. A sequential screening strategy had the lowest cost per CF birth avoided. In this strategy, the first partner was screened with a standard test that identifies 85% of carriers. The second partner was screened with an expanded test if the first partner's screen was positive. This strategy identified 75% of anticipated CF births at a cost of $367,000 each. This figure does not include the lifetime medical costs of caring for a patient with CF, and it assumes that couples who identify a pregnancy at risk will choose to have prenatal diagnosis and termination of affected pregnancies. The cost per CF birth identified is approximately half this figure when couples plan two children. Conclusions. The cost-effectiveness of CF carrier screening depends greatly on couples' reproductive plans. CF carrier screening is most cost-effective when it is performed sequentially, when the information is used for more than one pregnancy, and when the intention of the couple is to identify and terminate affected pregnancies. These conclusions are important for policy considerations regarding population-based screening for CF, and may also have important implications for screening for less common diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0272989x9801800209

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 21

  1. U.S. Congress, Office of Technology Assessment. Cystic Fibrosis and DNA Tests, 1992, Implications of Carrier Screening, OTA-BA-532
  2. 10.2105/AJPH.86.5.684 · doi:10.2105/ajph.86.5.684
  3. 10.1097/00005650-199105000-00007 · doi:10.1097/00005650-199105000-00007
  4. Lieu TA, 1994, Obstet Gynecol, 84, 903
  5. Beaudet AL, 1992, Am J Hum Genet, 50, 439
  6. 10.1007/BF00291675 · doi:10.1007/bf00291675
  7. 10.1093/clinchem/34.5.933 · doi:10.1093/clinchem/34.5.933
  8. Uhlmann WR., 1992, Persp Genet Counseling, 14, 7
  9. Bureau of Labor Statistics., 1992, Employer Costs for Employee Compensation
  10. Pauly MV., 1968, Am Econ Rev, 58, 531
  11. 10.1016/S0002-9378(12)90875-3 · doi:10.1016/s0002-9378(12)90875-3
  12. 10.1177/096914139500200107 · doi:10.1177/096914139500200107
  13. 10.2105/AJPH.81.8.992 · doi:10.2105/ajph.81.8.992
  14. 10.2105/AJPH.82.5.723 · doi:10.2105/ajph.82.5.723
  15. 10.1177/0272989X9601600208 · doi:10.1177/0272989x9601600208
  16. Mulivor RA, 1987, Am J Hum Genet, 40, 131
  17. Wilson RD, 1986, Obstet Gynecol, 67, 352
  18. Mackenzie WE, 1988, Obstet Gynecol, 71, 81
  19. 10.1111/j.1471-0528.1985.tb03049.x · doi:10.1111/j.1471-0528.1985.tb03049.x
  20. 10.1001/jama.1976.03270140023016 · doi:10.1001/jama.1976.03270140023016
  21. Crandall BF, 1980, Obstet Gynecol, 56, 625

Cited by

See all 375

Metadata

Authors
Asch, D. A., Hershey, J. C., Dekay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F., Giardine, R., Kant, J. A., & Mennuti, M. T.
Venue
Medical Decision Making
Published
1998-01
Volume
18
Issue
2
Pages
202-212
ISSN
  • 0272-989X (ISSN-L)
  • 1552-681X
OpenAlex
W2614452305
Cited by
375
References
20
FWCI
9.59
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes. https://app.cochat.ai/papers/10.1177/0272989x9801800209
The paper
Asch, D. A., Hershey, J. C., Dekay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F., Giardine, R., Kant, J. A., & Mennuti, M. T. (1998). Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes. Medical Decision Making. https://doi.org/10.1177/0272989x9801800209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.